Andrea Sottoriva
- Head of Computational Biology Research Centre, Biologia Computazionale
- Research Group Leader, Sottoriva Group
Andrea Sottoriva è il responsabile del Centro di ricerca di Biologia Computazionale di Human Technopole.
La ricerca di Andrea si focalizza sullo sviluppo di nuovi approcci computazionali per misurare i processi di evoluzione dei tumori nei pazienti, con lo scopo di effettuare previsioni dello sviluppo della malattia e progettare nuove strategie di trattamento che mirano a controllare la resistenza ai farmaci.
Dopo la laurea in informatica presso l’Università di Bologna nel 2006, ha conseguito un master in scienze computazionali presso l’Università di Amsterdam nel 2008. Durante gli studi del master ha, inoltre, svolto attività di ricerca all’Istituto Nazionale di Fisica Nucleare e delle Alte Energie (NIKHEF) dei Paesi Bassi dove ha lavorato all’esperimento del telescopio per neutrini ANTARES.
Nel 2012 ha ottenuto un dottorato di ricerca in biologia computazionale dall’Università di Cambridge, dove ha lavorato presso il centro di ricerca di Cancer Research UK.
Dopo il post-dottorato presso la University of Southern California, ha avviato il suo laboratorio presso l’Institute of Cancer Research di Londra nel 2013, dove nel 2018 è diventato vicedirettore del Center for Evolution and Cancer e poi direttore nel 2020.
È autore di numerosi studi pubblicati su prestigiose riviste scientifiche tra cui Science, Nature, Nature Genetics e Cancer Discovery. Tra i suoi articoli figurano “The co-evolution of the genome and epigenome in colorectal cancer” (Nature, 2022), “Phenotypic plasticity and genetic control in colorectal cancer evolution” (Nature, 2022), “Subclonal reconstruction of tumors by using machine learning and population genetics” (Nature Genetics, 2020), “Detecting repeated cancer evolution from multi-region tumor sequencing data” (Nature Methods, 2018), “Longitudinal liquid biopsy and mathematical modelling of clonal evolution forecast waiting time to treatment failure in a phase II colorectal cancer clinical trial” (Cancer Discovery, 2018), e “Patient-derived organoids model treatment response of metastatic gastrointestinal cancers” (Science, 2018).
Nel 2016 il Cancer Research UK gli ha conferito il prestigioso premio “Future Leaders in Cancer Research”.
Contatti
Segui
Pubblicazioni Selezionate
-
08/2024 - Nature
The genomic landscape of 2,023 colorectal cancers
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2,3,4,5,6,7,8,9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC […]
-
07/2024 - Nature Cancer
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics requires quantitative measurements in controlled clinical trials. We mapped genomic intratumor heterogeneity in locally advanced prostate cancer using 642 samples from 114 individuals enrolled in clinical trials with a 12-year median follow-up. We concomitantly assessed morphological heterogeneity using deep learning in 1,923 histological sections […]
-
03/2023 - Nature Genetics
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors
In cancer, evolutionary forces select for clones that evade the immune system. Here we analyzed >10,000 primary tumors and 356 immune-checkpoint-treated metastases using immune dN/dS, the ratio of nonsynonymous to synonymous mutations in the immunopeptidome, to measure immune selection in cohorts and individuals. We classified tumors as immune edited when antigenic mutations were removed by […]
-
10/2022 - Nature
The co-evolution of the genome and epigenome in colorectal cancer
Colorectal malignancies are a leading cause of cancer-related death1 and have undergone extensive genomic study2,3. However, DNA mutations alone do not fully explain malignant transformation4,5,6,7. Here we investigate the co-evolution of the genome and epigenome of colorectal tumours at single-clone resolution using spatial multi-omic profiling of individual glands. We collected 1,370 samples from 30 primary cancers and […]
-
10/2022 - Nature
Phenotypic plasticity and genetic control in colorectal cancer evolution
Genetic and epigenetic variation, together with transcriptional plasticity, contribute to intratumour heterogeneity1. The interplay of these biological processes and their respective contributions to tumour evolution remain unknown. Here we show that intratumour genetic ancestry only infrequently affects gene expression traits and subclonal evolution in colorectal cancer (CRC). Using spatially resolved paired whole-genome and transcriptome sequencing, […]
Previous page